Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
暂无分享,去创建一个
H. Akaza | O. Ogawa | M. Murai | S. Naito | H. Yamanaka | T. Kitamura | S. Kagawa | M. Namiki | T. Tsukamoto | Y. Hirao | S. Hinotsu | M. Usami
[1] J. Goodwin,et al. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. , 2006, Journal of the National Cancer Institute.
[2] P. Carroll,et al. Androgen‐deprivation therapy as primary treatment for localized prostate cancer , 2006, Cancer.
[3] H. Akaza. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective , 2006, Cancer science.
[4] J. Goodwin,et al. Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma , 2005, Cancer.
[5] H. Akaza,et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. , 2004, Japanese journal of clinical oncology.
[6] M. Cooperberg,et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. , 2003, Journal of the National Cancer Institute.
[7] Y. Homma,et al. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5‐year follow‐up , 2003, BJU international.
[8] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .